



POSTERS

EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3

E. Filippi¹, A. Armstrong², J. F. Merola³, M. Megna⁴, X. Man⁵, M. Honma⁶, J-M. Carrascosa⁷, R. Chughtai⁷, K. Fotiou⁸, S. Sabatino⁸, M. Ngantcha⁸, A. Pinter⁹

¹Eli Lilly Italia S.p.A, Florence, Italy; ²University of California, Los Angeles, CA, USA; ³University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁴University of Naples Federico II, Naples, Italy; ⁵Zhejiang University, Hangzhou, China; ⁶Asahikawa Medical University, Asahikawa, Japan; ⁷Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁸Eli Lilly and Company, Indianapolis, IN, USA; ⁹University Hospital Frankfurt, Frankfurt, Germany

Keywords: Uncover-3, Psoriasis.

Background. The National Psoriasis Foundation recommends evaluating treatment response at Week12, with a target body surface area (BSA) $\leq 1\%$ affected and an acceptable response of $\text{BSA} \leq 3\%$. European consensus emphasize a shift from relative outcomes such as Psoriasis Area and Severity Index (PASI) scores of 90/100 towards absolute endpoints including $\text{PASI} \leq 22$. Early achievement and long-term maintenance of these treat-to-target (T2T) outcomes are important, providing patients with more days of minimal disease burden.

Methods. UNCOVER-3 (NCT01646177) was a multicenter, randomized, double-blind, placebo-controlled study of ixekizumab in patients with moderate-to-severe psoriasis³. This post-hoc analysis examined T2T outcomes in patients from UNCOVER-3 receiving the label dose of ixekizumab (N=385). Baseline demographics and patient characteristics were similar to those previously presented⁴. Early and maintained response was defined as achievement of T2T goals at Week12 maintained at 5 years (Week264). Assessments included absolute $\text{PASI} \leq 2$, absolute $\text{PASI} \leq 1$, $\text{BSA} \leq 3\%$, and $\text{BSA} \leq 1\%$, reported as observed. No statistical testing for sig-

nificance was conducted.

Results. At Week12, absolute $\text{PASI} < 2$ and $\text{PASI} < 1$ response rates were achieved by 71.7% (n=276/385) and 68.1% (n=262/385) of patients; among responders with available observed data at Week264, 94.5% (n=156/165) and 81.3% (n=126/155) maintained absolute $\text{PASI} \leq 2$ and $\text{PASI} \leq 1$ responses, respectively. Additionally, $\text{BSA} < 3\%$ and $\text{BSA} < 1\%$ response rates were achieved by 62.1% (n=239/385) and 50.9% (n=196/385) of patients at Week12; among these responders, 97.7% (n=128/131) and 88.7% (n=102/115) maintained these targets at Week264, respectively.

Conclusions. These findings demonstrate that early and continuous treatment with ixekizumab results in long-term improvements in skin clearance to 5 years across clinically important T2T outcomes consistent with guidelines recommendations.

References

1. Armstrong A, et al. *Dermatol Ther* (Heidelb). 2024;14(4):933-952.
2. Mahil SK, et al. *Br J Dermatol*. 2019;182(6):1047-1053.
3. Gordon KB, et al. *N Engl J Med*. 2016;375(4):345-356.
4. Rosmarin D, et al. AAD Meeting 2021, poster presented.